Posted by Michael Wonder on 04 Feb 2022
FDA approves treatment for adults with rare type of anaemia
4 February 2022 - FDA has approved Enjaymo (sutimlimab-jome) infusion to decrease the need for red blood cell transfusion due to haemolysis (red blood cell destruction) in adults with cold agglutinin disease.
The effectiveness of Enjaymo was assessed in a study of 24 adults with CAD who had a blood transfusion within the past six months.
